Background: Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant, Allergan, Dublin, Ireland), an intra-vitreal biodegradable implant indicated for cystoid macular edema due to variable causes. One of its known complications is implant migration to the anterior chamber, causing corneal edema that in some cases might be irreversible. Reported risk factors for device migration are open or defective lens capsule and prior history of vitrectomy. We present a case of dexamethasone implant migration through a congenital iris coloboma in a pseudophakic patient with intact lens capsule. Case presentation: 56-year-old pseudophakic man with a history of congenital iris coloboma, myopia, retinal tears and a Branch Retinal Vein Occlusion (BRVO) with subsequent Cystoid Macular Edema (CME) which was resistant to anti-VEGF medications but responsive to corticosteroids. He presented with sudden painless decreased vision in his left eye, eight weeks after dexamethasone implant (Ozurdex®) injection to the same eye. Upon presentation he was diagnosed with corneal edema caused by anterior chamber migration of the implant. He was referred for immediate surgical intervention and the implant was extracted, with the edema completely resolved within two weeks post-op. Conclusions: This is the first case reported of implant migration through an iris coloboma in the setting of intact posterior capsule. In addition, we describe a novel approach for implant removal surgery that is simple and efficient. This case sheds a light on another risk factor that should be taken into consideration in the management of this patient population.